Spots Global Cancer Trial Database for bioavailability
Every month we try and update this database with for bioavailability cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Relative Bioavailability Study of Enzalutamide in Prostate Cancer Patients | NCT01902251 | Prostate Cancer Pharmacokinetic... | Enzalutamide ta... Enzalutamide ca... | 18 Years - | Astellas Pharma Inc | |
| Bioavailability and Food Effect Study of Gelatin Formulation and Immediate Release Tablet Formulation of Afuresertib | NCT02040480 | Cancer | GSK2110183 Gela... GSK2110183 IR T... | 18 Years - 40 Years | GlaxoSmithKline | |
| Availability & Effect of Post-OP Ketorolac on Ovarian, Fallopian Tube or Primary Peritoneal Cancer | NCT01670799 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | Ketorolac | 18 Years - | New Mexico Cancer Care Alliance | |
| A Study to Assess the Relative Bioavailability of Process Variants of Selumetinib in Healthy Male Volunteers | NCT02322749 | Healthy Volunte... | selumetinib 75m... selumetinib 75m... selumetinib 75m... | 18 Years - 45 Years | AstraZeneca | |
| Availability & Effect of Post-OP Ketorolac on Ovarian, Fallopian Tube or Primary Peritoneal Cancer | NCT01670799 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | Ketorolac | 18 Years - | New Mexico Cancer Care Alliance | |
| A Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian Cancer | NCT03400306 | Cancer - Ovaria... | Veliparib, caps... Veliparib, tabl... Carboplatin Paclitaxel | 18 Years - 99 Years | AbbVie | |
| Bioavailability and Effectiveness of Transdermally Administered Morphine | NCT00125684 | Cancer Pain | morphine | 18 Years - 65 Years | AHS Cancer Control Alberta | |
| A Bioavailability Study of GSK1363089 in Subjects With Solid Tumors | NCT00742261 | Solid Tumours | GSK1363089 | 18 Years - | GlaxoSmithKline | |
| Bioavailability and Food Effect of the Original Gelatin Formulation and Two New Formulations of Afuresertib in Normal Healthy Volunteers | NCT01827644 | Cancer | Afuresertib GC ... Afuresertib HPM... Afuresertib ECT... Afuresertib GC ... Afuresertib HPM... Afuresertib ECT... | 18 Years - 40 Years | GlaxoSmithKline | |
| A Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian Cancer | NCT03400306 | Cancer - Ovaria... | Veliparib, caps... Veliparib, tabl... Carboplatin Paclitaxel | 18 Years - 99 Years | AbbVie | |
| A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors | NCT04672460 | Advanced Solid ... Solid Tumors Ovarian Cancer Breast Cancer Prostate Cancer NSCLC Pancreatic Canc... Colorectal Canc... | TALZENNA capsul... Talazoparib sof... Talazoparib sof... | 18 Years - 70 Years | Pfizer | |
| A Study to Assess the Relative Bioavailability of Process Variants of Selumetinib in Healthy Male Volunteers | NCT02322749 | Healthy Volunte... | selumetinib 75m... selumetinib 75m... selumetinib 75m... | 18 Years - 45 Years | AstraZeneca | |
| Tolerability and Bioavailability of Utidelone Capsule in Patients With Advanced Solid Tumors | NCT05700084 | Advanced Solid ... | Utidelone Capsu... Drug A Utidelon... Drug A Utidelon... Drug B Utidelon... Drug B Utidelon... Capecitabine Utidelone Capsu... | 18 Years - 70 Years | Beijing Biostar Pharmaceuticals Co., Ltd. | |
| A Bioavailability Study of GSK1363089 in Subjects With Solid Tumors | NCT00742261 | Solid Tumours | GSK1363089 | 18 Years - | GlaxoSmithKline | |
| Bioavailability and Food Effect Study of Gelatin Formulation and Immediate Release Tablet Formulation of Afuresertib | NCT02040480 | Cancer | GSK2110183 Gela... GSK2110183 IR T... | 18 Years - 40 Years | GlaxoSmithKline | |
| A Study to Assess the Absolute Bioavailability of Oral Selumetinib in Healthy Male Volunteers. | NCT02238782 | Healthy Volunte... | selumetinib 75m... [14C] selumetin... | 18 Years - 65 Years | AstraZeneca | |
| Bioavailability and Food Effect of the Original Gelatin Formulation and Two New Formulations of Afuresertib in Normal Healthy Volunteers | NCT01827644 | Cancer | Afuresertib GC ... Afuresertib HPM... Afuresertib ECT... Afuresertib GC ... Afuresertib HPM... Afuresertib ECT... | 18 Years - 40 Years | GlaxoSmithKline | |
| Bioavailability and Food Effect Study of Gelatin Formulation and Immediate Release Tablet Formulation of Afuresertib | NCT02040480 | Cancer | GSK2110183 Gela... GSK2110183 IR T... | 18 Years - 40 Years | GlaxoSmithKline |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
